Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Rang in aandelen #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Aandeelprijs
$0.051239
Laatst gesynchroniseerd: 2025-11-24
Marktkapitalisatie
$1.38M
Verandering (1 dag)
-4.48%
Verandering (1 jaar)
-54.57%
Land
NO
Handel BerGenBio ASA (BGBIO)

Categorie

Koersgeschiedenis voor BerGenBio ASA (BGBIO)
Hoogste slotkoers: $0.08 op 2025-11-01

Laagste slotkoers: $45.81 op 2017-04-01
Koersgeschiedenis van BerGenBio ASA van 2017 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 36.04%
2025 -90.51%
2024 -63.90%
2023 -73.76%
2022 -63.83%
2021 -44.23%
2020 73.06%
2019 -30.98%
2018 -3.30%
2017 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE